Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Holcombe E. Grier, MD


Pediatric Hematology/Oncology

Make an Appointment

Physician

  • Distinguished Staff
  • Professor of Pediatrics, Emeritus, Harvard Medical School

Centers/Programs

Clinical Interests

  • Ewing sarcoma
  • Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)
  • Osteosarcoma
  • Rhabdomyosarcoma

Contact Information

Bio

Dr. Grier received his MD from the University of Pennsylvania in 1976, and then trained in pediatrics, internal medicine, and infectious disease at the University of North Carolina. He joined Dana-Farber Cancer Institute in 1984. He is a past president of the American Society of Pediatric Hematology/Oncology and is a member of the steering committee for Bone Tumors in the Children's Oncology Group.

Board Certification:

  • Internal Medicine, 1980
  • Pediatric Hematology/Oncology, 1990
  • Pediatrics, 1983

Fellowship:

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology

Residency:

  • North Carolina Memorial Hospital

Medical School:

  • University of Pennsylvania School of Medicine

Recent Awards:

  • Harvard Medical School Faculty Prize for Excellence in Teaching [Years III and IV] 2008
  • Stephen Sallan Leadership Award, Dana Farber Cancer Institute, Boston, MA 2007
  • Ronald L Chard, Jr. Memorial Lecture, Childrens Hospital and Memorial Medical Center, Seattle, WA. 2008
  • Harvard Medical School Community Service Award 2009
  • Charles A. Janeway Award for Excellence in Clinical Teaching, Children's Hospital House Staff, Boston 1992

Research

Pediatric Sarcomas


At the Children's Oncology Group, we work on the design and implementation of studies regarding Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas. The Children's Oncology Group is a consortium of cancer treatment centers across the United States, Canada, and other countries. Dr. Grier is an active member of the Bone Tumor Disease Committee and the Soft Tissue Sarcoma Committee of this group. As part of the Pediatric Solid Tumor Center at Dana-Farber/Boston Children's, we help organize laboratory and clinical cross talk. We are also involved in cancer survivor studies that focus on the late effects of chemotherapy. These studies are led by Dr. Lisa Diller at the David B. Perini Jr. Quality of Life Clinic at Dana-Farber Cancer Institute. In addition, we participate in a study of the best application of palliative care through our work with the Pediatric Advanced Care Team, led by Dr. Joanne Wolfe.

Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.{line break}Clin Cancer Res 2003;9:5442-53.

Marcus KJ, Shamberger R, Litman H, von Allmen D, Grupp SA, Nancarrow CM, Goldwein J, Grier HE, Diller L. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol 2003;25:934-40.

Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005:2004-11.

Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.

Mack JW, Grier HE. The day one talk. J Clin Oncol 2004;22:563-6.

Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 2005;23:4031-8.

Granowetter L, Womer RB, Devidas M, Krailo MD, Wang C, Bernstein ML, Marina N, Leavey PJ, Gebhardt M, Healey JH, Shamberger RC, Goorin AM, Miser J, Meyer M, Arndt CAS, Sayler S, Marcus KJ, Perlman EJ, Dickman PS, Grier HE: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.J Clin Oncol 27:2536-2541, 2009.

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana G350
Boston, MA 02215
Get Directions

Ratings

Top